Login / Signup

OBSIDIAn - real world evidence of Originator to BioSImilar Drug switch in juvenile idiopathic arthritis.

Ilaria MaccoraNiccolò LombardiGiada CrescioliAlessandra BettiolRoberto BonaiutiIlaria PagniniValerio ManiscalcoEdoardo MarraniMaria Vincenza MastroliaClaudia RavaldiRita ConsoliniMarco CattaliniNiccolò LombardiGabriele Simonini
Published in: Rheumatology (Oxford, England) (2021)
Our real-life results seem to confirm the efficacy and safety profile of switching from originator of ADA and ETA to their respective BIOs also in paediatric patients with JIA.
Keyphrases
  • juvenile idiopathic arthritis
  • disease activity
  • intensive care unit
  • emergency department
  • rheumatoid arthritis
  • adverse drug
  • drug induced